








+

3/25



+




FIG. 4



+

5/25




FIG. 5

+

6/25

+




FIG. 6

+

7/25

+





FIG. 7

+


8/25

FIG. 8 - Platelet Count (X 10³/μl blood)



9/25

FIG. 9 - Neutrophil Values ($\times 10^3/\mu\text{l}$ blood)



10/25

FIG. 10A – Mean and Median Platelet Count

		Cycle 1			Cycle 2			Cycle 3		
	Screen	Day 1	Day 8	Day 15	Day 1	Day 8	Day 15	Day 1	Day 8	Day 15
Mean	274,000	266,000	169,000	143,000	408,000	300,000	156,000	419,000	307,000	155,000
Median	268,000	273,000	186,000	135,000	418,000	347,000	174,000	387,000	362,000	171,000

11/25

FIG. 10B – Mean and Median Neutrophil Count

		Cycle 1			Cycle 2			Cycle 3		
	Screen	Day 1	Day 8	Day 15	Day 1	Day 8	Day 15	Day 1	Day 8	Day 15
Mean	5800	4100	2200	1900	5200	2900	1800	2900	2900	2000
Median	5500	4200	2100	1300	4100	2500	1600	3100	1800	1500

12/25

FIG. 11A






FIG. 11B



14/25

FIG. 11C



15/25

FIG. 11D




FIG. 11E





FIG. 11F



18/25

FIG. 12A

Patient number	Sites of metastatic disease	CA 19-9 (Baseline)	CA 19-9 (Cycle 4, Day 1)	RECIST Criteria Tumor Response and Patient Status
2001	Liver, both lungs	4,775	9,926	Stable disease; liver and lung metastases reduced in size; on study
6002	Liver, aortocaval and hilar nodes	125	15	Stable disease; liver and nodal metastases reduced in size; on study
6003	Both lungs	6,186	2,405	Stable disease; on study
6004	Periaortic and gastric nodes; unresectable pancreatic mass	6,275	348	Partial response; on study
6006	Multiple liver metastases	395	108	Stable disease; on study
6007	Liver, left and right adrenals, unresectable pancreatic mass	70,086	10,286*	Partial response; on study
7001	Porta hepatis, supraclavicular nodes with unresectable pancreatic mass	2,138	288	Partial response; on study
7002	"Dozens" of liver metastases	483	80	Partial response; on study
8001	Periaortic and mesenteric nodes and unresectable pancreatic mass	11	20	Stable disease; on study
9001	Liver, lung, unresectable pancreatic mass	326	69	Partial response; on study

*CA19-9 at Cycle 3, Day 1

FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12E




FIG. 12F




FIG. 13A
Platelet count (X 10³/μl blood)




FIG. 13B

Platelet count (X $10^3/\mu\text{l}$ blood)

